The University of Tennessee, Memphis Hepatitis C Cooperative Research Center will use studies of HCV/host interactions to determine why African American patients with HCV respond poorly to standard therapy (interferon and ribavirin). Hepatitis C is common, 1.8% of all Americans, but is even more common among African Americans, and in persons living in poverty. In Memphis, 55% of the population is African American, 34% of whom live below the poverty line. In a previous study, we documented a response rate of only 5% in this population, contrasted with 40% in whites. We propose to systematically characterize the differences between African Americans and whites by allelic variations in cellular ligands/receptors for HCV (Project 1). In Project 2, we will continue to develop an in vitro system for studying HCV, a chimeric VSV virus with the hepatitis C E1 and E2 envelope proteins expressed on its surface. We will use this model to characterize virus/cell interactions, testing antibodies to specific dominant quasispecies, contrasting our African American patients with whites. We will further characterize the putative receptor for HCV, CD81, to define its associated proteins, possible co-receptors (Project 3). These data will interface back to our patients as we search for allelic variations between African Americans and whites to explain the differences in response to therapy. Using the surrogate virus model, we will also screen libraries of small molecules to search for compounds that can block E2/CD81 binding (Project # African American population responds so poorly. Understanding this phenomenon will provide insights into why present day therapy is still only moderately successful in all populations, will allow us to predict who is more likely to respond, and will pave the way to developing better therapy for this emerging health problem.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI048216-02
Application #
6374638
Study Section
Special Emphasis Panel (ZAI1-LIG-M (M1))
Program Officer
Sawyer, Leigh A
Project Start
2000-08-01
Project End
2005-07-31
Budget Start
2001-08-01
Budget End
2002-07-31
Support Year
2
Fiscal Year
2001
Total Cost
$738,193
Indirect Cost
Name
University of Tennessee Health Science Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163
Weintraub, Steven J; Fleckenstein, Jaquelyn F; Marion, Tony N et al. (2013) Vitamin D-binding protein gene polymorphisms may contribute to the racial disparity in genotype 1 chronic hepatitis C treatment outcome. Hepatology 58:1864
Weintraub, Steven J; Fleckenstein, Jacquelyn F; Marion, Tony N et al. (2012) Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response. Am J Clin Nutr 96:1025-31
Kuntzen, Thomas; Timm, Joerg; Berical, Andrew et al. (2008) Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769-78
Park, Vicki M; Mason, Barbara C; Krushkal, Julia et al. (2007) Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure. Dig Dis Sci 52:2540-9
He, Xiao-Song; Ji, Xuhuai; Hale, Matthew B et al. (2006) Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 44:352-9
Pfeffer, Lawrence M; Kim, Jong-Gwan; Pfeffer, Susan R et al. (2004) Role of nuclear factor-kappaB in the antiviral action of interferon and interferon-regulated gene expression. J Biol Chem 279:31304-11
Miller, Mark A; Lavine, Christy L; Klas, Sheri D et al. (2004) Recombinant replication-restricted VSV as an expression vector for murine cytokines. Protein Expr Purif 33:92-103
Matsuura, Y; Tani, H; Suzuki, K et al. (2001) Characterization of pseudotype VSV possessing HCV envelope proteins. Virology 286:263-75